Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner; Courtney D. DiNardo; Frederick R. Appelbaum; Charles Craddock; Hervé Dombret; Benjamin L. Ebert; Pierre Fenaux; Lucy A. Godley; Robert P. Hasserjian; Richard A. Larson; Ross L. Levine; Yasushi Miyazaki; Dietger Niederwieser; Gert Ossenkoppele; Christoph Röllig; Jorge Sierra; Eytan M. Stein; Martin Stuart Tallman; Hwei Fang Tien; Jianxiang Wang; Agnieszka Wierzbowska; Andrew H. Wei; Bob Löwenberg

doi:10.1182/blood.2024025409

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Hartmut Döhner^*, Courtney D. DiNardo, Frederick R. Appelbaum, Charles Craddock, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Lucy A. Godley, Robert P. Hasserjian, Richard A. Larson, Ross L. Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M. Stein, Martin Stuart Tallman, Hwei Fang Tien, Jianxiang WangAgnieszka Wierzbowska, Andrew H. Wei, Bob Löwenberg

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Comment/debate › peer-review

12 Scopus citations

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Original language	English (US)
Pages (from-to)	2169-2173
Number of pages	5
Journal	Blood
Volume	144
Issue number	21
DOIs	https://doi.org/10.1182/blood.2024025409
State	Published - Nov 21 2024

Funding

The authors acknowledge R\u00FCdiger Hehlmann for his continuous generous support of these recommendations on behalf of the European LeukemiaNet. H. D\u00F6hner is supported by Sonderforschungsbereich 1074 \u201CExperimental models and clinical translation in leukemia\u201D and Forschungsgruppe 2674, project A02 \u201CGenetic landscape of acute myeloid leukemia in older patients,\u201D both funded by the Deutsche Forschungsgemeinschaft. A.H.W. is supported by the Australian National Health and Medical Research Council, Victorian Cancer Agency, Metcalf Family Fellowship, and the Medical Research Future Fund. C.D.D. is supported by the Leukemia & Lymphoma Society Scholar in Clinical Research Award. Contribution: H. D\u00F6hner, C.D.D. A.H.W. and B.L. wrote the draft version of the manuscript; and all authors reviewed and approved the final version of the manuscript.

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2024025409

Cite this

Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., Tien, H. F., ... Löwenberg, B. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood, 144(21), 2169-2173. https://doi.org/10.1182/blood.2024025409

@article{e8d1e8c32ff64c839138fa577b950a9f,

title = "Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations",

abstract = "The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.",

author = "Hartmut D{\"o}hner and DiNardo, {Courtney D.} and Appelbaum, {Frederick R.} and Charles Craddock and Herv{\'e} Dombret and Ebert, {Benjamin L.} and Pierre Fenaux and Godley, {Lucy A.} and Hasserjian, {Robert P.} and Larson, {Richard A.} and Levine, {Ross L.} and Yasushi Miyazaki and Dietger Niederwieser and Gert Ossenkoppele and Christoph R{\"o}llig and Jorge Sierra and Stein, {Eytan M.} and Tallman, {Martin Stuart} and Tien, {Hwei Fang} and Jianxiang Wang and Agnieszka Wierzbowska and Wei, {Andrew H.} and Bob L{\"o}wenberg",

note = "Publisher Copyright: {\textcopyright} 2024 American Society of Hematology",

year = "2024",

month = nov,

day = "21",

doi = "10.1182/blood.2024025409",

language = "English (US)",

volume = "144",

pages = "2169--2173",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "21",

}

Döhner, H, DiNardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, J, Wierzbowska, A, Wei, AH & Löwenberg, B 2024, 'Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations', Blood, vol. 144, no. 21, pp. 2169-2173. https://doi.org/10.1182/blood.2024025409

TY - JOUR

T1 - Genetic risk classification for adults with AML receiving less-intensive therapies

T2 - the 2024 ELN recommendations

AU - Döhner, Hartmut

AU - DiNardo, Courtney D.

AU - Appelbaum, Frederick R.

AU - Craddock, Charles

AU - Dombret, Hervé

AU - Ebert, Benjamin L.

AU - Fenaux, Pierre

AU - Godley, Lucy A.

AU - Hasserjian, Robert P.

AU - Larson, Richard A.

AU - Levine, Ross L.

AU - Miyazaki, Yasushi

AU - Niederwieser, Dietger

AU - Ossenkoppele, Gert

AU - Röllig, Christoph

AU - Sierra, Jorge

AU - Stein, Eytan M.

AU - Tallman, Martin Stuart

AU - Tien, Hwei Fang

AU - Wang, Jianxiang

AU - Wierzbowska, Agnieszka

AU - Wei, Andrew H.

AU - Löwenberg, Bob

PY - 2024/11/21

Y1 - 2024/11/21

N2 - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

AB - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

UR - http://www.scopus.com/inward/record.url?scp=85203490901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85203490901&partnerID=8YFLogxK

U2 - 10.1182/blood.2024025409

DO - 10.1182/blood.2024025409

M3 - Comment/debate

C2 - 39133932

AN - SCOPUS:85203490901

SN - 0006-4971

VL - 144

SP - 2169

EP - 2173

JO - Blood

JF - Blood

IS - 21

ER -

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this